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Fragile sites of the genome have long been known as a specific type of DNA lesions, 
which arises from an imperfect completion of replication before the cell enters mitosis. Rare 
fragile sites are present only in a small part of the human population. Thus, they seem to be 
generally less attractive than common fragile sites, which are an intrinsic part of the human 
genome. However, the molecular basis of rare fragile sites is examined better. 
Being a DNA damage, fragile sites are subjects of the cellular mechanisms leading to 
their repair. Unrepaired lesions might evolve to more dangerous forms, which may contribute 
to genomic rearrangement typical of malignant transformation. It is therefore possible that 










Fragilní místa genomu jsou známa jako zvláštní typ poškození DNA, které vzniká kvůli 
neúplnému dokončení replikace před vstupem buňky do mitózy. Vzácná fragilní místa se 
vyskytují pouze u malé části lidské populace. Obecně by tedy mohla být tedy méně atraktivní 
než běžná fragilní místa, jež jsou normální součástí lidského genomu, přesto je lépe 
prozkoumána molekulární struktura vzácných fragilních míst. 
Fragilní místa -coby specifický druh poškození DNA- jsou předmětem buněčných 
opravných mechanismů. Pokud tyto léze nejsou opraveny, vznikají nebezpečnější formy 
poškození, které přispívají k přestavbám genomu typickým pro maligní transformaci. Je tedy 
možné, že přetrvávající exprese fragilních míst je jedním z mechanismů vedoucích k vývoji 
neoplastických lézí. 
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Maintenance of the genome in its intact form is important for a proper function of the 
whole cell, which is necessary for the long-term survival of multicellular organisms. This 
stability may be disrupted as a consequence of various environmental factors (e.g. ionizing 
irradiation) or damaging products of normal metabolism as free oxygen radicals. Both 
exogenous and endogenous agents cause mutations or lesi ns on DNA, which may be 
harmless, but more often deleterious or even lethal. During the evolution, cells created several 
mechanisms to protect themselves from the consequences of these potentially dangerous 
events. There is a number of distinct repair mechanisms arising from the variety of DNA 
lesions. Besides the direct repair, the DNA damage response comprises cell cycle 
checkpoints, which halt cell cycle progression until the repair process is completed, and 
programmed cell death. When any component of this machinery is altered, neoplastic 
development is likely to occur (Kastan and Bartek, 2004).  
Fragile sites are a specific type of DNA damage. They represent lesions unrepaired 
during cell cycle interphase. Their appearance on metaphase chromosomes indicates that 



















2. Rare fragile sites 
 
2.1. Definition and categorization of fragile sites 
Fragile sites are specific chromosomal loci, visible as constrictions or gaps on 
metaphase chromosomes, which appear after a specific cell culture treatment (Figure 1) 
(Sutherland, 1979). They were first observed in blood cells of a woman, who had been 
previously repeatedly treated by x-ray irradiation for recurrent eczematous dermatitis 
(Debakan, 1965). Before one of them was linked to fragile X syndrome, fragile sites had been 
considered to be a cytogenetical artefact. Nowadays, many of their intriguing properties have 
been found out, including their involvement in genomic instability and tumorigenesis 
(Sutherland et al., 1998). The list of all published fragile sites is given in Table 1. 
According to their frequency within the population, fragile sites were classified as 
common or rare. Common (or constitutive) fragile sites have been found in genomes of all 
individuals (Arlt et al, 2003), while rare (or heritable) fragile sites only in less than 5% of 
human population (Schwartz et al., 2006). Under particular in vitro conditions, the 
chromosomal fragility is displayed by broken chromatids (usually both), which results in 
forming acentric fragments, deleted chromosomes, triradial figures and similar abnormalities 
that occur on metaphase spreads (Sutherland, 1979). Further division of fragile sites is 
therefore provided by their inducing factors. Common fragile sites are detectable after 
aphidicolin, 5-azacytidine or 5-bromodeoxyuridine (BrdU) treatment. Rare fragile sites 
distinguish folate sensitive, distamycin A-inducible and BrdU-requiring groups (Handt et al., 




Figure 1. Karyotype of a woman heterozygous for FRA10B (arrow) and homozygous 
for FRA16B (arrows) after cell treatment with berenil (derivate of distamycin A). Adopted 




Table 1. (previous page) The list of all fragile site  published in Schwartz et al.(2006) 
 
 
2.2. General characteristics of rare fragile sites 
Cytogenetically, fragile site is a part of chromatin, which ceases to compact for mitosis. 
While the normal regions of DNA finish replication before metaphase, the fragile regions 
seem to remain unreplicated or even single-stranded. This can result in forming of 
chromosomal breaks in a certain percentage of cells. Even though they might manifest 
spontaneously, their inducers cause replication stres , further enhancing their expression 
(Sutherland, 2003). Furthermore, the expressed rare fr gile sites were found to expel 
nucleosomes in the presence of their inducers. Thisattribute was strongly correlated with a 
length of the sequence (Wang et al., 1996; Hsu and Wang, 2002). It was therefore possible to 
assess the chromosomal constrictions at fragile sites to be the consequences of perturbed 
nucleosome formation. 
Some fragile sites follow Mendelian inheritance (FRA16B, FRA10B), while others do 
not: FRAXA is transmitted differentially by males and females (Sutherland, 2003). 
Rare fragile sites consist of different copy numbers of certain repeat sequences. Thus, 
they were generally determined as subjects of dynamic mutation process (Yu et al., 1997). 
Their increasing copy number positively correlates with the rate of their instability, both 
somatic and intergenerational, and severity of disease, if they are associated with any 
(Richards and Sutherland, 1997). The stability of fragile sites is also influenced by the 
sequences flanking the expanded alleles (Sutherland and Richards, 1995). However, the folate 
sensitive fragile sites show higher instability, which may be due to their shorter repeat 
sequences that are more prone to replication slippage than their longer counterparts 
(Sutherland and Richards, 1999). 
 
 
2.3. Folate sensitive rare fragile sites 
The majority of rare fragile sites is induced either by folate or thymidine deficiency in 
cell culture media, folate metabolism inhibitors (e.g. methotrexate) or dTTP synthesis 
inhibitors. Their frequency also rises with increasing pH, which is useful for acquisition of 
maximal in vitro expression (Sutherland, 1979). Seven of them were positionally cloned and 
found to be expanded CCG microsatellite repeats, showing polymorphism in the copy number 
in individuals (Schwartz et al., 2006; Winnepenninckx et al., 2007). Alleles express fragility 
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after reaching the threshold of 100-1000 copies (Pearson and Sinden, 1998). Lower copy 
numbers are not cytogenetically visible, although these of 50-1000 copies in length are 
thought to be premutations, which expand into full mutations during oogenesis, but not during 
spermatogenesis (Sutherland et al., 1999). Expanded alleles have the contiguous CpG islands 
hypermethylated, which seems to be the consequence rath r than the cause of the mutation 
(Nancarrow et al., 1994). Short nonfragile sequences ar  stabilized by interruptions, whereas 
fragile alleles or premutations contain long stretch s of perfect repeats, thus being prone to 
further expansion (Handt et al., 2000a) 
CCG trinucleotide repeats can form non-B DNA secondary structures (Figure 2): intra-
strand hairpin structures, slipped strand DNA and tetrahelical structures (reviewed in Pearson 
and Sinden, 1998). Stability of such an organization of these sequences depends on their 
length and purity. Hairpins can lower the differenc between energy levels of normal and 
slipped state, thus providing stability for a strand slippage, which is necessary for the dynamic 
mutation process (Gacy et al., 1995). Tetrahelical structures may occur immediately when 
CCG-rich DNA is unpaired and contribute to the perturbation of DNA replication. 
Obstruction of polymerase progression would further facilitate strand slippage on repeated 
sequences (Usdin and Woodford, 1995). 
Only three members of folate sensitive group are generally considered to be clinically 
significant, FRAXA, FRAXE, and FRA11B. FRAXA, which localizes to Xq27.3, is 
associated with fragile X syndrome. At its position n normal chromosome, there are 5 to 55 
copies of CCG repeat, which increase of about 200 copies in premutation carriers. Full 
mutation consists of more than 230 copies of CCG repeat with adjacent highly methylated 
CpG sequences. Female carriers of premutation may rarely display the fragile X, which is 
probably due to the hypermethylation of this chromosome that is necessary for expression of 
the fragile site. Fragile X syndrome itself is caused by transcriptional silencing of the FMR1 
gene, in whose 5´ untranslated region a repeat expansion appears. Expansion of FRAXE 
repeats is followed by non-specific X-linked mental retardation (Sutherland, 2003). Third 
fragile site on X chromosome, FRAXF, have never been documented to cause any clinical 
problem. Rare fragile sites on X chromosome are cytogenetically indistinguishable, thus 
molecular analysis has to be done to determine a potential pathological significance 
(Sutherland and Baker, 2000). FRA11B was demonstrated to map within 5´ UTR of the CBL2 
proto-oncogene. Although it had been previously associated with Jacobsen syndrome, the 
deletion breakpoint found in some patients was proposed to localize proximally to this fragile 
site (Jones et al., 1995). Recently, FRA12A was cloned and demonstrated to contain the 
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DIP2B gene, whose down-regulation may be associated with mental retardation 
(Winnepenninckx et al., 2007). 
Interestingly, folate sensitive type of fragile regions has not been observed in species 
other than humans (Sutherland and Richards, 1999). The homozygous carriers of folate 
sensitive fragile sites on autosomal chromosomes have never been reported and the 
heterozygotes comprise only 1% of the human population. It was therefore considered that 
homozygosity may lead to spontaneous abortion or risk of defects of genetic origin in children 
with heterozygous parents (Sutherland and Baker, 2000). 
 
 
                            
 
Figure 2. Unusual secondary structures formed by fragile sequences: intra-strand 
hairpins (left), slipped-strand DNA (middle) and tetrahelical structures (right). Adopted from 
Schwartz et al. (2006) 
 
 
2.4. Non-folate sensitive rare fragile sites 
These fragile sites are present in 6-8% of human population (Sutherland and Baker, 
2000) and are divided in the two groups mentioned above. Distamycin A inducible group has 
5 members to date. Their expression is caused by specific compounds that bind to the minor 
groove of DNA, which also comprises Hoechst 33258, netropsin and berenil (Sutherland, 
2003). 
Second, BrdU requiring group, is represented by onltwo members. Their inducer can 
be incorporated into the DNA during replication instead of thymine. It is used in 
concentration that only partially inhibits replication (Schwartz et al., 2006).  
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Propensity of these fragile sites to form non-B DNA structures has not been examined 
yet. But since this attribute was proposed to be necessary for repeat expansion (Gacy et al., 
1995), it was hypothesised, that all types of rare fragile sites shared this property (Hewett et 
al., 1998).  
Two non-folate sensitive rare fragile sites have ben cloned, both containing AT-rich 
minisatellite repeats, which expand under conditions required (Schwartz et al., 2006). 
Compared to folate sensitive fragile sites, expanded alleles of these fragile sites are up to 20 
times longer (Sutherland et al., 1998). They were demonstrated to be late replicating, although 
FRA10B showed delay only on the distal side of the expanded allele. However, delayed 
replication may contribute to fragility, but it is probably not a sufficient condition for 
expression of fragile site, because gaps are displayed only by a fraction of cells (Handt et al., 
2000b). 
The most common rare fragile site, FRA16B, is induced either by minor-groove binding 
chemicals or by BrdU (Felbor et al., 2003). When induced with berenil, it occurred in almost 
100% of metaphases (Sutherland and Richards, 1995). The homozygotes have been found to 
be normal, without any gene affected, at least no essential one (Hocking et al., 1999). The 
probands of this study were also heterozygous for an ther rare fragile site. However, possible 
relation between both aberrations has not been examined, as in other cases of this 
phenomenon (Sutherland and Baker, 2003). FRA16B was first determined as an allelic 
expansion of 33-base pair consensus sequence located at 16q22.1, proposed to be a region of 
genomic instability. Normal alleles ranged from 7 to 12 copies, rising up to 2000 upon 
amplification (Yu et al., 1997). Then a novel 35-bp minisatellite repeat was described in a 
Japanese carrier, differing in insertion of two nucleotides from the previous one (Figure 3) 
(Yamauchi et al., 2000). This study also suggested that the length of the expanded region 
might be more significant for cytogenetic expression of this fragile site than its AT content. 
 
 
5‘ - ATA TAT TAT ATA TTA TAT CTA ATA A       TAT ATA TA - 3‘ 
5‘ - ATA TAT TAT ATA TTA TAT CTA ATA A       TAT ATC TA – 3‘ 
5‘ - ATA TAT TAT ATA TTG TAT CTA ATA ATA  TAT ATC TA – 3‘ 
5‘ - ATA TAT TAT ACA TTG TAT CTA ATA ATA  TAT ATC TA – 3‘ 
 
Figure 3. Repeat motif of FRA16B reported by Yu et al. (1997) (first and second row) 
and by Yamanauchi et al. (2000) (third and fourth row). Inserted nucleotides are shown in 
bold. 
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FRA10B can be induced only by BrdU (or BrdC) and has not been found to cause any 
disease (Sutherland, 2003). Homozygous children report d in early study were phenotypically 
normal (Sutherland, 1981). This fragile site is located at 10q25.2. FRA10B repeats vary 
between 16 and 52 bp in length (in single individual). Four groups of alleles were designated: 
small normal (<1 kb), from which progressively arise ntermediate (1-4 kb), large normal (4-5 
kb) and expressing one (>5 kb). This finding is consistent with the dynamic mutation process 
of fragile site formation. Surprisingly, sequences of these two fragile sites share 26 identical 
bases (Hewett et al., 1998). 
 
 
2.5. Rare fragile sites and evolution 
The evolutionary biologists have long been considere  existence of chromosomal 
regions that have been repeatedly used in genome rearrangements. Recent findings (Ruiz-
Herrera et al., 2006) confirmed a non-uniform distribution of these evolutionary ‘hot spots’, 
some of which are conserved during the chromosome evolution. The evolutionary breakpoints 
were demonstrated to span tandem repeats and fragile sites, although this association was 
statistically significant just for the rare ones. This study proposed human genome to be a 
composition of fragile regions, conserved in mammals and disposed to reorganization, and 
regions lying between them without showing evolutionary plasticity. 
 
 
2.6. Common properties of rare and common fragile sites 
Both types of fragile sites have the same cytogenetical manifestation, thus there have 
been many attempts to find out their possible common characteristics on molecular level 
(Schwartz et al., 2006). 
Above all, fragile sites share perturbed or late replication in terms of their induction 
mode. Then, all the classes form stable secondary DNA structures, which may obstruct the 
replication elongation. Finally, they share a cytogenetical manifestation. 
Common fragile sites have not been elicited to comprise any expanded repeats, but 
interrupted shorter repeats. Thus, the fragility of these sequences may be accounted on their 
AT-richness and flexibility (Ried et al., 2000). Stretches of AT-rich islands at common fragile 
sites and repeat motifs of FRA10B and FRA16B were found to be highly similar. These two 
rare fragile sites also showed flexibility comparable to common fragile sites. Normal alleles 
of FRA16B and FRA10B stretch the same regions on human genome as common fragile sites 
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FRA16C and FRA10E, respectively. Furthermore, some f the rare fragile sites, which have 
not been cloned yet, span the same chromosomal bands as common fragile sites inducible by 
aphidicolin treatment. It was therefore considered that common fragile sites might expand into 
rare fragile site (Zlotorynski et al., 2003). This study also proposed that fragility would result 































3. Involvement of rare fragile sites in cancer 
 
3.1. Fragile sites and double strand breaks 
Propensity of fragile sites to form hairpins is thepossible reason for their capability to 
delay replication because it takes some time to get ov r these structures. Under further 
replication stress, the fragile regions entirely halt replication (Arlt et al., 2003). Abnormal 
stimulation of cell proliferation in precancerous stages was suggested to cause such 
replication stress (Gorgoulis et al., 2005). The perturbed replication may be followed by 
replication fork collapse and formation of DNA double strand breaks (DSBs) (Lundin et al., 
2002), which are one of the most dangerous forms of DNA damage. They appear by 
simultaneous breakage of both DNA strands at sites that are close enough to be impossible to 
be kept together (Jackson, 2002). This event switches signal transduction pathways to repair 
these lesions on DNA. When these pathways fail, either cell death or chromosomal 
rearrangements occur (Khanna and Jackson, 2001).  
As mentioned above, inducers of fragility can inhibit the progression of replication 
forks. The low concentration of the replication inhibitor, which only slows the process, led to 
formation of DSBs in some genomic regions, whereas the higher concentration, followed by 
replication arrest, caused lesions throughout the entire genome (Schwartz et al., 2005). 
The main DSB repair pathways are homologous recombination (HR) and 
nonhomologous end joining (NHEJ). They function in partly overlapping manner. The 
replication inhibitors arrest cell cycle in late G1 and S phase. Stalled replication forks can 
result in forming of single strand nicks, followed by DSBs. The stimulation of HR is 
enhanced by prolonged DNA replication block and increasing number of these lesions. It 
proceeds mostly by gene conversion. While HR occurs mo tly in the late phase, NHEJ would 
repair DNA damage in the early response (Saintigny et al., 2001). NHEJ acts by simple 
ligation of two free DNA ends without requirement of their homology (Khanna and Jackson, 
2001). The roles of these two pathways may be also cell cycle-dependent, NHEJ being 
engaged in all phases, whereas HR mostly in late S/G2 (Rothkamm et al., 2003). More 
recently, HR was proposed to be a secondary event e in terms of repair action itself, DSBs 
being firstly fixed by NHEJ due to higher safety of the process (Iliakis et al., 2004). However, 
this study inquired into ionizing radiation induced l sions, thus considering that the selection 
of the repair pathway may depend on the inducing factor. This is in agreement with previous 
findings (Rothkamm et al., 2003), which demonstrated he preferential role of HR in 
regeneration of DSBs produced by treatment with aphidicolin. Furthermore, HR is also the 
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sole process in restoration of slowed replication frks without presence of DSBs (Lundin et 
al., 2002). 
Once broken, neither fragile chromosomes, nor cut fragments seem to restore their 
telomeres (Villa et al., 1997). Thus, they are prone to forming aberrant structures that may 
occur through breakage-fusion-bridge (BFB) cycles (Figure 4). Fusion of chromosomes with 
broken ends or shortened telomeres results in formation of dicentric chromosome, followed 
by new breakage at anaphase. This event generates chromosome with inverted duplication of 
terminal sequences, which would enter another cycle, until it gains telomeric sequences 
(McClintock, 1942). The BFB mechanism was also suggested to act towards the amplification 
of certain genomic regions necessary for successful cancer development (e.g. oncogenes) 
(Albertson, 2006). Expression of fragile sites was demonstrated to be the major cause of this 
event at its early stages. The distance between the fragile sites involved in amplification 
determines the length of the amplified region. When the amplicon is accumulated in sufficient 






Figure 4. Breakage-fusion-bridge cycles, model with two fragile sites at one 




Hypoxia was proposed to induce fragile sites in vivo and to cause fusion of acentric 
extrachromosomal molecules called double minutes (DMs), which often contain amplified 
oncogenes. Moreover, these were demonstrated to reintegrate into fragile sites, resulting in 
formation of chromosomal expansions visible as homogen usly stained regions (HSRs) that 
are frequently observed in solid tumours. Repeated induction of fragile sites was shown to 
produce large marker chromosomes with accumulated genes (Coquelle et al., 1998). 
Taken together, the results of these two French studies mentioned above clearly show 
that fragile sites are associated with both extrachromosomal and intrachromosomal 
amplification of oncogenes. 
 
 
3.2. Rare fragile sites in leukemic patients 
Chromosomal rearrangements associated with fragile site expression were considered to 
be the cause of neoplastic transformation. This was especially examined in various cases of 
leukemia. An early study (Mules et al., 1989) investigated possible hereditary predisposition 
to cancer in relatives of patients with lymphoid leuk mia, who have chromosomal 
rearrangements at rare fragile sites. Although the male relatives of the cases in older age 
groups displayed tendency to lung cancer, it was not statistically significant. Furthermore, 
hereditary proneness to cancer might show earlier ag  at onset, but younger relatives were not 
affected. Thus, cancer predisposition in these families due to chromosomal aberrations caused 
by rare fragile sites was not proved. However, with the numbers of relatives in this study, 
possible slight tendency to cancer was undetectable. 
Another study examined a single family, which inherited autosomal dominant acute 
myelogenous leukemia (Horwitz et al., 1997). Even though LOD score (logarithm of odds; a 
statistical test used for the analysis of the genetic linkage between traits or markers in 
pedigrees, i.e. to determine the probability of recombination) provided linkage to 16q22 locus, 
expansion of FRA16B as a cause of leukemia in this family was excluded. 
Chromosomal aberrations were demonstrated to occur non-randomly in cells of patients 
with chronic myeloid leukemia (Fundia et al., 2000). This report proposed chromosomal 
instability to appear as a consequence of clastogenic environment in cancer cells, thus being a 
demonstration of a neoplastic process. 
Cells from patients with chronic lymphocytic leukemia frequently contain chromosome 
11q deletions. Since clusters of CCG repeats including those of FRA11B are known to 
localize on distal region of longer arm of the chromosome 11, they were examined to be 
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involved in progression of the disease (Auer et al., 2001). Although chromosomal breakpoints 
were situated on other CCG rich regions, minimal deleted region spans FRA11B. It was 
therefore suggested that there might exist previously nrevealed fragile sites or that unstable 
repeats of fragile site would influence stability of the region far away from its own position. 
Moreover, placed in deleted region, contribution of FRA11B to neoplastic development is 
hard to detect. 
Possible implications of fragile sites in cancer may also occur through epigenetic 
mechanisms. Genes of non-coding RNAs, called microRNAs (miR genes) were found to 
frequently coincide with fragile sites and genomic regions associated with cancer (Calin et al., 
2004). MicroRNAs usually regulate expression of other genes through translation blockade 
(Huppi et al., 2007). Two miRs were previously demonstrated to be down-regulated or 
deleted in most of chronic lymphocytic leukemia cases (Calin et al., 2002). 
 
 
3.3. Possible role of rare fragile sites in anticancer therapy 
The AT-rich minisatellite of fragile site FRA16B was proposed to serve as nuclear 
matrix attachment region (MAR) in leukemic cells, whereas normal alleles were found in the 
loop DNA of normal cells (Jackson et al., 2003). Since MARs are implicated in initiation of 
DNA replication, they are crucial for tumour cells. Thus, these sequences were demonstrated 
to be preferentially targeted by potent antitumour drugs like bizelesin, which give rise to high 
number of lesions on AT-rich DNA (Woynarowski et al., 2001). Given the difference in 
composition between the normal and the expanded FRA16B, this might be beneficial for the 
efficient removal of cancerous cells. However, not all MARs described to date are AT islands 
and vice versa (Woynarowski, 2004). 
Interestingly, one of the inducers or this fragile site, BrdU, was demonstrated to fortify 
the binding of MARs to nuclear matrix. This structural alteration would change expression of 




3.4. Fragile sites as consequences of failure of the genome maintenance mechanisms 
Reports on individuals with more than one fragile st offer a possibility that some trans-
acting agent, which brings about one fragile sequence expansion, may act on more regions 
prone to copy-number alterations (Sutherland and Baker, 2003). Lack of proteins involved in 
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genome maintenance was proved to induce common fragile site expression (Casper et al., 
2002, Musio et al., 2004). Since cytogenetical apperance and defective replication are shared 
by both types of fragile sites, it might be some mutation in members of signal transduction 
pathways, cell cycle checkpoints or other mechanisms comprised in genome surveillance, 
which is responsible for or contribute to fragility. This is in concert with finding of 
chromosomal instability in Seckel syndrome, a rare utosomal recessive disorder, which is 
manifested by dwarfism, mental retardation, microcephaly, micrognathia and other facial 
malforations. Clinical features of this disease are equivalent to those of Nijmegen breakage 
syndrome and LIG4 syndrome, both of which being associated with altered DNA damage 
response. Seckel syndrome was proposed to be an outcome of low level of ataxia-
teleangiectasia and Rad3-related protein (ATR), which is sufficient to prevent cell death, but 





Figure 5. DNA DSBs lead primarily to ATM activation, whereas ssDNA attract ATR-
ATRIP complex. Both kinases then phosphorylate their r spective downstream targets, 





On the way from DNA damage to its repair, there is a group of less or more important 
proteins employed in various steps of the process: sensors that recognize the lesion, kinases of 
transduction cascade and effector proteins, which provide DNA repair, cell cycle arrest, or 
apoptosis (Khanna and Jackson, 2001). The regions of single stranded DNA (ssDNA), which 
appear at stalled replication forks (Figure 5), DSBs or sites of other types of DNA damage 
(e.g. mismatch repair), are recognized and covered by replication protein A (RPA) (Namiki 
and Zou, 2006). These protein structures attract ATRIP (ATR interacting protein) (Zou and 
Elledge, 2003), which may also interact with ssDNA itself, but this interaction seems to be of 
secondary significance (Namiki and Zou, 2006). ATRIP is phosphorylated by ATR and these 
two proteins create a stable complex in human cells, which appears as intranuclear foci at 
sites of DNA damage. Furthermore, their expression is mutually dependent (Cortez et al., 
2001) and loss of ATR leads to embryonic lethality a  early stage of the development, that 
was caused by chromosomal fragmentation (Brown and Baltimore, 2000). RPA is necessary 
not only for formation of ATR-ATRIP nuclear foci atsites of DNA damage, but also for the 
activation of downstream targets of ATR, which was demonstrated for Chk1 (checkpoint 
kinase 1) and Rad17. Besides ATR-ATRIP, Rad17 and Ra 9-Rad1-Hus1 complexes also 
contribute to the recognition of lesions on DNA (Zou and Elledge, 2003). 
ATR was previously thought to exist in a stably active form, which only relocalizes to 
actual DNA lesions. Recent findings demonstrated that it is activated by interaction with 
TopBP1 (Figure 6, left), which would alter the confrmation of ATR-ATRIP complex. The 
transient character of this interaction allows ATR to pursue its protective function in a 
dynamic and efficient manner (Kumagai et al., 2006). ATR is consequently capable to 
directly phosphorylate majority of its substrates with exception of Chk1 (Liu et al., 2000), 
which is also regulated by Claspin (Liu et al., 2006). Activated Chk1 initiates cell cycle arrest 
by inhibition of Cdc25C (Sanchez et al., 1997), thus preventing mitotic entry. Phosphatase 
Cdc25A, which also promote cell cycle progression, was demonstrated to be degraded by 





Figure 6. Both ATR (left) and ATM (right) are required for the cell response to DNA 




Another kinase crucial for DNA damage response is ataxi  teleangiectasia mutated 
protein (ATM), which is particularly involved in cellular response to DSBs. In normal, 
undamaged cells it exists in dimeric or multimeric form, which is dissoluted by 
autophosphorylation in the presence of DNA damage (Figure 5). Active monomers 
subsequently phosphorylate substrates (Bakkenist and K stan, 2003). Another research group 
proposed that ATM activation is provided by MRN (Mre11-Rad50-Nbs1) complex, which 
senses DSBs and unwinds DNA ends (Lee and Paull, 2005). This study did not confirm the 
necessity of ATM autophosphorylation. However, ATM is recruited to DSBs by interaction 
with C terminus of Nbs1 (Falck et al., 2005).ATM targets various substrates as p53 by 
phosphorylation at serine 15 (Banin et al., 1998, Canman et al., 1998), Chk2 (chekpoint 
kinase 2), or H2AX, which is also phosphorylated by ATR at sites of stalled replication forks 
(Ward and Chen, 2001). Phosphorylated form of H2AX, γH2AX, then binds MDC1 (mediator 
of DNA damage checkpoint protein 1) and this interaction is necessary for formation of 
53BP1 (p53 binding protein 1), Nbs1 (Nijmegen breakage syndrome 1) and active ATM foci 
at sites of damaged DNA (Figure 6, right). ATM is al o required to maintain γH2AX in its 
activated form (Stucki et al., 2005).  
In response to DSBs in S and G2 phases, both ATM and ATR are required (Figure 6). 
ATM triggers Mre11 nuclease activity, which subsequntly generate stretches of ssDNA that 
are coated with RPA. These intermediates attract ATR, whose activated downstream effector 
Chk1 cooperates with ATM-activated Chk2 in cell cycle arrest (Jazayeri et al., 2006). ATM 
and ATR are both members of the phosphoinositide-3-kinase-related protein kinase (PIKK) 
family and they share some important targets as p53 or BRCA1 (breast cancer 1) (Tibbetts et 
al., 2000), which are both tumour suppressors and their loss results in malignancy (Niida and 
Nakanishi, 2006). The PIKK family also comprises DNAPKcs (DNA-dependent protein 
kinase catalytic subunit). This enzyme interacts with C terminus of Ku80 to form the DNA-
PK complex, which is involved in NHEJ DSBs repair (Falck et al, 2005). The DNA damage 
repair is provided by HR and NHEJ, which were discus ed above. 
Interestingly, some large common fragile sites span ge es involved in cellular response 
to various types of stress (including replication stre s), as FRA15A, which contain retinoic 
acid receptor-related orphan receptor alpha (RORA) gene (Zhu et al., 2006). Lying in highly 
unstable regions, these genes are frequently delete during neoplastic development and at 
least two of them have been demonstrated to play a role in tumour suppression. However, 





Fragile sites are unstable regions of mammalian genom s. According to Schwartz et al. 
(2006), there are 89 common and 32 rare fragile sites in human genome. Indeed, not all of 
them have been revealed to date. Although some rare fragile sites have been characterized at 
the molecular level, the connection between the certain structure and respective inducing 
factors of all types of fragile alleles remains elusive (Handt et al., 2000a). It is also still 
unclear, which factors are responsible for expression of fragility in vivo (Richards, 2001).  
Some of rare fragile sites were previously associated with alterations in gene expression 
resulting in mental retardation (Sutherland, 2003). However, in terms of cell cycle 
progression, their major importance is their ability to cause replication stalling or even DNA 
DSBs. Such lesions on DNA require quick and efficient repair. It was recently reported, that 
at early stages of neoplastic transformation, pathwys of the DNA damage response are 
activated. In developed malignant tumours, these mechanisms were diminished (Bartkova et 
al., 2005). The authors of this study therefore proposed, that mutations causing defects in 
DNA damage signalling and repair are the steps to genomic instability associated with 
development of cancer.  
DNA damage response was recently proposed as a necessary component of replication 
and processing of human telomeres (Verdun and Karlseder, 2006). Since telomere attrition 
and genomic instability are both hallmarks of neoplastic transformation, it is tempting to 
speculate that fragile sites might indicate mutations in repair pathways or somehow reflect 
precancerous cell environment. The demonstration of fragile site induction by hypoxic 
conditions in vitro (Coquelle et al., 1998) further supports this idea. Moreover, hypoxia may 
cause a selective pressure for transformed cells, which lost functional p53 or other 
components of checkpoint control mechanisms (Hammond et al., 2002).  
Although fragile sites are usually placed to regions, which are deleted in cancer, 
FRA16B was found in its expanded form in leukemic and colon carcinoma cell lines (Jackson 
et al., 2003). Possible contribution of fragile site  o carcinogenesis by oncogene amplification 
was demonstrated only in vitro in Chinese hamster cell line (Coquelle et al., 1997). However, 
if fragile sites has causal role in neoplastic development or they are just its consequences 
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